Digoxin: Cardiac Glycoside and Na+/K+ ATPase Pump Inhibitor for Heart Failure & CHIKV Research

Executive Summary: Digoxin is a validated cardiac glycoside for research on heart failure, arrhythmia, and antiviral applications, functioning primarily as a potent Na+/K+-ATPase pump inhibitor (APExBIO). At concentrations ≥33.25 mg/mL, it is soluble in DMSO but insoluble in water and ethanol (APExBIO). Digoxin exhibits dose-dependent inhibition of chikungunya virus (CHIKV) infection in multiple human and animal cell lines (Lundberg et al., 2019, DOI). In canine models of congestive heart failure, intravenous administration of 1–1.2 mg improves cardiac output and reduces right atrial pressure (Smith et al., 1993, PubMed). APExBIO’s Digoxin (SKU B7684) is provided at >98.6% purity and is accompanied by HPLC, NMR, and MSDS documentation for reproducibility (APExBIO).

Biological Rationale

Digoxin is a reference compound in cardiovascular and infectious disease research. It is classified as a cardiac glycoside, a group of compounds historically used in the management of heart failure and arrhythmias (NCBI Bookshelf). Digoxin’s dual pharmacological profile—modulating cardiac contractility and inhibiting viral replication—makes it a versatile tool for translational research (see this article, which this dossier extends by specifying dose-dependent antiviral effects and detailed workflow parameters).

In cardiovascular research, Digoxin’s ability to enhance myocardial contractility is leveraged in both cellular and animal models of heart failure. Its use in arrhythmia research stems from its effect on cardiac conduction and refractoriness. In virology, emerging evidence supports Digoxin’s role as an inhibitor of CHIKV and potentially other viral pathogens by disrupting host cell ion homeostasis (Nature Communications).

Mechanism of Action of Digoxin

Digoxin acts as a potent and selective inhibitor of the Na+/K+-ATPase pump. This membrane-bound enzyme exchanges intracellular sodium (Na⁺) for extracellular potassium (K⁺), a process critical for maintaining electrochemical gradients in excitable tissues (NCBI Bookshelf). By blocking this pump, Digoxin increases intracellular sodium concentration. This leads to reduced activity of the sodium-calcium exchanger, thereby increasing intracellular calcium levels. Elevated calcium enhances cardiac contractility (positive inotropy) and can modulate cardiac rhythm.

In the context of viral infection, such as CHIKV, Digoxin’s disruption of Na+/K+-ATPase activity impairs viral entry or replication. This effect is dose-dependent and has been validated in human osteosarcoma (U-2 OS), primary human synovial fibroblasts, and Vero cells at concentrations from 0.01 to 10 μM (Lundberg et al., 2019).

Evidence & Benchmarks

• Digoxin inhibits Na+/K+-ATPase activity at nanomolar concentrations in vitro, as confirmed by enzymatic assays (APExBIO).
• In canine models of congestive heart failure, intravenous Digoxin (1–1.2 mg) increases cardiac output by up to 30% and reduces right atrial pressure within 30 minutes (Smith et al., 1993, PubMed).
• Digoxin impairs CHIKV infection in U-2 OS, human synovial fibroblasts, and Vero cells in a concentration-dependent manner (0.01–10 μM) (DOI).
• Solubility in DMSO is ≥33.25 mg/mL; insoluble in water and ethanol (APExBIO QC data, product page).
• High purity (>98.6%) is validated by HPLC and NMR, supporting reproducibility across experiments (internal content).

Applications, Limits & Misconceptions

Digoxin is widely used in research spanning cardiac contractility, arrhythmia, and viral inhibition. Its dual mechanism makes it suitable for dissecting the Na+/K+-ATPase signaling pathway and evaluating antiviral responses in cell culture. The reagent is provided as a solid and must be reconstituted in DMSO for experimental use; solutions should be used promptly and not stored long-term due to stability limits (APExBIO).

This article extends previous discussions by specifying solubility, purity, and validated cell/animal model data, offering workflow-focused guidance.

Common Pitfalls or Misconceptions

• Not water- or ethanol-soluble: Attempting to dissolve Digoxin in these solvents results in incomplete solution and unreliable dosing.
• Long-term storage of solutions: Digoxin in DMSO is not stable for prolonged periods; fresh preparation is mandatory for reproducibility.
• Assuming uniform effects across models: Efficacy and toxicity vary between species and cell types; always validate dosing and endpoints for each system.
• Extrapolating clinical efficacy from animal or in vitro data: Preclinical results do not guarantee equivalent outcomes in human clinical scenarios.
• Overlooking purity verification: Use only high-purity, QC-validated sources (such as APExBIO B7684) for reproducibility.

Workflow Integration & Parameters

Preparation: Digoxin (SKU B7684) is supplied as a solid; dissolve at ≥33.25 mg/mL in DMSO at room temperature. For cell assays, dilute to final concentrations (e.g., 0.01–10 μM) in culture medium. For animal studies, use validated administration protocols (e.g., intravenous in dogs at 1–1.2 mg per animal) (Lundberg et al., 2019).

Controls: Always include vehicle (DMSO) controls and verify compound identity/purity by HPLC or NMR as supplied (APExBIO QC data).

Data reproducibility: Use freshly prepared solutions and document storage, handling, and dosing parameters for all experiments.

For further workflow guidance, refer to this scenario-driven guide, which this dossier updates by including the latest purity, solubility, and cell-line specificity data.

Conclusion & Outlook

Digoxin remains a cornerstone tool for dissecting cardiac and viral pathophysiology in preclinical research. Its validated mechanism as a Na+/K+-ATPase inhibitor and its demonstrated antiviral activity against CHIKV make it valuable for both cardiovascular disease research and emerging infectious disease models. APExBIO’s Digoxin (SKU B7684) provides high-purity, reproducible performance, with comprehensive QC data and workflow support (product page). Researchers are advised to follow strict protocols for preparation and use, validate dosing in their chosen systems, and interpret results within the model-specific context. Ongoing studies may further expand the recognized antiviral spectrum and mechanistic insights of Digoxin.